Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshReset Filter
              refresh Reset Filter
              price-trend All Drugs in Dev.

              Product Type

              Companies

              Mithra Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              Post An Enquiry Post An Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth

              Cell & Gene Therapy Manufacturing

              Participation Not Confirmed

              Update your events

              ExeVir and Mithra Announce Manufacturing Collaboration for Innovative Covid-19 Treatm...

              Lead Product(s): llama-derived VHH-Fc Antibody

              Therapeutic Area: Infections and Infectious Diseases Product Name: XVR011

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Mithra CDMO

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 15, 2021

              Details:

              XVR011 is a single domain-based anti-SARS-CoV-2 antibody (llama-derived VHH-Fc) optimized for stability, safety, broad neutralizing capability and excellent manufacturability.

              PharmaCompass__DigitalAd